Impedimed's share price is up by 55% since its stunning announcement on Monday morning
Stockbroker
Impedimed's share price is up by 55% since its stunning announcement on Monday morning. This was regarding the 'Centers for Medicare and Medicaid Services' assigning a reimbursement rate of US$112.67 for Impedimed's test. This compares to company guidance of US$30 - US$50. Matthijs Smith previously used US$30 in his models. This change has obviously resulted in a step change in his valuation, which increased by a remarkable 164% from $0.70 to $1.85. This may yet leave further upside, as his model assumes that the company only receives US$85 per test. More upside may also come from testing protocols that stipulate more frequent testing. Many clinics are testing their patients 17 times over a four-year period, and more frequently if they do develop lymphoedema. This compares to our model, which assumes eight tests per patient in this time frame. Impedimed has already gained 211% since Matthijs initiated on 12th march at $0.225, and the stock now trades at his previous valuation of $0.70. With the new upgrade in price target to $1.85, the stock firmly remains a buy. Research here: (VIEW LINK)
Canaccord Genuity Group is a leading independent, full-service financial services firm. Canaccord Genuity has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual,...
Expertise
No areas of expertise
Canaccord Genuity Group is a leading independent, full-service financial services firm. Canaccord Genuity has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual,...
Expertise
No areas of expertise